Literature DB >> 28453750

NovoTTF: where to go from here?

Timothy F Cloughesy1, Andrew B Lassman2.   

Abstract

Mesh：

Year:  2017        PMID： 28453750      PMCID： PMC5464445          DOI： 10.1093/neuonc/nox014

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  7 in total

1.  Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?

Authors:  Monika E Hegi; Roger Stupp
Journal:  Neuro Oncol       Date:  2015-09-15       Impact factor: 12.300

2.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Authors:  Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin
Journal:  Eur J Cancer       Date:  2012-05-18       Impact factor: 9.162

3.  The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma.

Authors:  F Bernard-Arnoux; M Lamure; F Ducray; G Aulagner; J Honnorat; X Armoiry
Journal:  Neuro Oncol       Date:  2016-05-13       Impact factor: 12.300

4.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.

Authors:  M D Walker; E Alexander; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; H A Norrell; G Owens; J Ransohoff; C B Wilson; E A Gehan; T A Strike
Journal:  J Neurosurg       Date:  1978-09       Impact factor: 5.115

5.  Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.

Authors:  M Westphal; Z Ram; V Riddle; D Hilt; E Bortey
Journal:  Acta Neurochir (Wien)       Date:  2006-02-17       Impact factor: 2.216

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

7.  Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Authors:  Roger Stupp; Sophie Taillibert; Andrew A Kanner; Santosh Kesari; David M Steinberg; Steven A Toms; Lynne P Taylor; Frank Lieberman; Antonio Silvani; Karen L Fink; Gene H Barnett; Jay-Jiguang Zhu; John W Henson; Herbert H Engelhard; Thomas C Chen; David D Tran; Jan Sroubek; Nam D Tran; Andreas F Hottinger; Joseph Landolfi; Rajiv Desai; Manuela Caroli; Yvonne Kew; Jerome Honnorat; Ahmed Idbaih; Eilon D Kirson; Uri Weinberg; Yoram Palti; Monika E Hegi; Zvi Ram
Journal:  JAMA       Date:  2015-12-15       Impact factor: 56.272
  7 in total
  6 in total

1.  Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.

Authors:  Andrew Yu; Nadia Faiq; Stacey Green; Albert Lai; Richard Green; Jethro Hu; Timothy F Cloughesy; Ingo Mellinghoff; P Leia Nghiemphu
Journal:  J Neurooncol       Date:  2017-07-01       Impact factor: 4.130

Review 2.  Updates in IDH-Wildtype Glioblastoma.

Authors:  Mary Jane Lim-Fat; James R Perry; Jawad M Melhem; Jay Detsky
Journal:  Neurotherapeutics       Date:  2022-05-31       Impact factor: 6.088

Review 3.  Tumor-Treating Fields for the treatment of glioblastoma: a systematic review and meta-analysis.

Authors:  Ohad Regev; Vladimir Merkin; Deborah T Blumenthal; Israel Melamed; Tehila Kaisman-Elbaz
Journal:  Neurooncol Pract       Date:  2021-04-20

4.  Current usage of tumor treating fields for glioblastoma.

Authors:  Andrew B Lassman; Adela E Joanta-Gomez; Peter C Pan; Wolfgang Wick
Journal:  Neurooncol Adv       Date:  2020-06-04

Review 5.  Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.

Authors:  Yuefeng Wang; Manjari Pandey; Matthew T Ballo
Journal:  Oncologist       Date:  2019-08-23

6.  Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Martin J B Taphoorn; Linda Dirven; Andrew A Kanner; Gitit Lavy-Shahaf; Uri Weinberg; Sophie Taillibert; Steven A Toms; Jerome Honnorat; Thomas C Chen; Jan Sroubek; Carlos David; Ahmed Idbaih; Jacob C Easaw; Chae-Yong Kim; Jordi Bruna; Andreas F Hottinger; Yvonne Kew; Patrick Roth; Rajiv Desai; John L Villano; Eilon D Kirson; Zvi Ram; Roger Stupp
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.